The use of biomarkers has significantly changed diagnostic thinking and more generally the management of emergency heart disease. But if the use of cardiac biomarkers in the management of heart disease in adults is no longer in doubt, there is currently no recommendation or expert consensus in children.
B-type natriuretic peptides have four missions:
 improve the diagnosis and, if their use is integrated into the decision-making algorithm in the face of dyspnea acute, and are also useful in the diagnosis of Acute and Chronic Heart Failure;
 determine the prognosis of heart failure;  participate in monitoring and any heart failure patient should have a reference BNP dosage, its
monitoring making it possible to identify patients at risk requiring a review of the therapeutic strategy;
 help optimize treatment. Thus, provided they are confronted with the clinic and keep their limitations in mind, they constitute a useful guide in the management of patients with heart failure. Most learned societies have so far incorporated the use of these tools into recommendations for good clinical practice. They contribute to the emergency referral decision. The number of publications devoted to these biomarkers has grown exponentially, which
denotes all the interest shown towards them. The few lines that follow will take stock of this thematic.